Gilder Gagnon Howe & Co. LLC Acquires 17,437 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 88.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 37,144 shares of the biopharmaceutical company’s stock after acquiring an additional 17,437 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Gilead Sciences were worth $3,431,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. HHM Wealth Advisors LLC boosted its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the sale, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at approximately $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 302,785 shares of company stock worth $30,540,875. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $103.17 on Friday. The firm has a market capitalization of $128.46 billion, a price-to-earnings ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The business’s 50-day moving average price is $109.21 and its 200-day moving average price is $98.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the business posted ($1.32) earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.06%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Bank of America boosted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $109.43.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.